{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:14:06Z","timestamp":1788012846981,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bullous pemphigoid (BP), an autoimmune bullous dermatosis, occurs predominantly in older individuals. Nemolizumab, a humanized monoclonal antibody against the interleukin (IL)\u201031 receptor A, is used to treat severe atopic dermatitis (AD) in Japan. However, it can cause several adverse events, such as exacerbation of AD, erythema, and eosinophilia. Herein, we describe a case of prurigo\u2010type AD developing BP after nemolizumab administration. A 62\u2010year\u2010old man with prurigo\u2010type AD and asthma presented with serious, refractory itching. After nemolizumab injection, his pruritus was relieved for 2\u2009days. However, on day 3, erythema with blisters and erosions suddenly appeared throughout his body. Pathological examination showed typical BP and the patient's serum anti\u2010BP180\u2010NC16a antibody level was 882.5\u2009U\/mL. Oral prednisolone (PSL) was initiated and nemolizumab was never used again. Despite high\u2010dose PSL, new blisters continued to develop, with a rapid elevation of anti\u2010BP180\u2010NC16a antibodies to 6930\u2009U\/mL. Adding high\u2010dose cyclosporine and intravenous gamma globulin reduced new blister formation after 9\u2009weeks, and PSL and cyclosporine were gradually tapered. Dupilumab, an anti\u2010IL\u20104 receptor antibody, was initiated after 16\u2009weeks, resulting in continued remission without PSL and cyclosporine. The sudden occurrence of BP in this case suggested that the patient had occult BP before the nemolizumab initiation and that nemolizumab exacerbated BP and made it overt. Blocking the IL\u201031 pathway may exacerbate inflammation in AD or BP, resulting in the acceleration of blister formation. This may be countered by blocking the IL\u20104\/13 pathway with dupilumab. To our knowledge, this is the first case of nemolizumab\u2010exacerbated BP.<\/jats:p>","DOI":"10.1111\/1346-8138.17171","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T17:29:30Z","timestamp":1710955770000},"page":"1252-1255","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A case of bullous pemphigoid following administration of <scp>anti\u2010IL<\/scp>\u201031 receptor A antibody"],"prefix":"10.1111","volume":"51","author":[{"given":"Ryosuke","family":"Masuyuki","sequence":"first","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-653X","authenticated-orcid":false,"given":"Emi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01383"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.03.018"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606490"},{"key":"e_1_2_7_6_1","unstructured":"PMDA.Guideline for promotion of optimal use nemolizumab (genetical recombination) (Trade name: Mitchga 60 mg syringe for subcutaneous injection) \u2013 Pruritus associated with atopic dermatitis. Pharmaceutical Evaluation Division Pharmaceutical Safety and Environmental Health Bureau Ministry of Health Labour and Welfare 2022:1\u201370."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16654"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.035"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)70077-X"},{"key":"e_1_2_7_10_1","first-page":"1132","article-title":"Pemphigoid nodularis \u2013 rare presentation of bullous pemphigoid: a case report and literature review","volume":"17","author":"Vornicescu C","year":"2019","journal-title":"Exp Ther Med"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885023"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02372-w"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.019"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111157"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2428"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908316"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:14:57Z","timestamp":1741767297000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/1346-8138.17171"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17171","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}